dopantin

Dopantin is a brand name used in several countries for a pharmaceutical product whose active ingredient is domperidone, a dopamine D2 receptor antagonist. It is primarily used as an antiemetic to prevent nausea and vomiting and to treat symptoms of gastroparesis by enhancing gastrointestinal motility. Domperidone works peripherally, increasing motility in the GI tract and helping to raise the tone of the lower esophageal sphincter. It crosses the blood–brain barrier poorly, which reduces central dopaminergic side effects relative to other dopamine antagonists.

Safety and regulatory status of Dopantin vary by country. Domperidone has been associated with cardiac risks, including QT interval prolongation and torsades de pointes, especially at higher doses or in individuals with electrolyte disturbances or underlying heart conditions, and when combined with other drugs that affect the QT interval. Because of these concerns, some jurisdictions have imposed strict dosing limits, restricted access, or removed domperidone from the market altogether. The United States Food and Drug Administration has not approved domperidone for any indication and has issued warnings about its use in the U.S. In other regions, domperidone products may be available by prescription or under restricted conditions.

Common formulations of Dopantin include tablet and oral suspension preparations, typically in 10 mg doses, prescribed or advised by a clinician. As with all medications, potential drug interactions (for example with QT‑prolonging agents, certain antibiotics or antifungals) and liver function considerations should be reviewed before use.